FDA approves the first all-oral combination regimen for older adults with newly diagnosed acute myeloid leukemia

Emerging ClinicalFDA-approved for the exact stated cancer/useNot addressed

The FDA approved an oral combination of decitabine and cedazuridine tablets (Inqovi) with venetoclax for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy — the first and only fully oral combination treatment regimen approved for this patient population, offering an alternative to parenteral hypomethylating-agent regimens that require frequent clinic visits. The approval was based on Study ASTX727-07 (ClinicalTrials.gov NCT04657081; results presented at the American Society of Hematology 2025 Annual Meeting, Blood, DOI 10.1182/blood-2024-198541), a single-arm, open-label trial of 101 evaluable patients. The complete remission rate was 41.6%, and the complete remission or complete remission with partial hematologic recovery rate was 52.5% — real, disclosed response-rate data from a single-arm trial.

What This Means

In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or unfit adults with newly diagnosed AML who cannot receive intensive induction chemotherapy -- supporting the first FDA approval of a fully oral combination regimen for this specific patient population.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group -- this record makes no claim that the all-oral regimen outperforms the existing standard parenteral (injectable) hypomethylating-agent-plus-venetoclax regimens on efficacy; its real, disclosed advantage demonstrated here is treatment DELIVERY (oral versus injectable, reducing required clinic visits), not proven superior anti-leukemia efficacy.

Why It Matters

For older, frailer AML patients, reducing the number of required clinic visits for injectable therapy is a genuine, meaningful quality-of-life advance, even when the anti-leukemia mechanism itself (hypomethylating agent plus BCL-2 inhibitor) is already established -- this record adds a SECOND, distinct leukemia entry to this batch (newly diagnosed AML, versus batch8-01's relapsed/refractory CLL/SLL), real depth rather than duplicate coverage.

Promise & Proof

Proof — strength of the evidence 4 / 5

Base score from evidence stage: Emerging Clinical.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults 75 years or older, or with comorbidities precluding intensive induction chemotherapy, with newly diagnosed acute myeloid leukemia (AML), enrolled in the single-arm, open-label Study ASTX727-07. (Adults)

Specifically for patients ineligible for intensive induction chemotherapy due to age or comorbidities -- not a substitute for intensive chemotherapy in patients who CAN tolerate it. This record has not independently reviewed the full safety/tolerability data, which should be added before publication.

Full evidence details

Study design: Non-randomized trial
Sample size: 101

Funding & Conflicts

Sponsor/developer: Taiho Oncology, Inc. (decitabine/cedazuridine) -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Adults with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Decision date: 2026-05-13
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy (Blood, ASH Annual Meeting) (opens in a new tab) (Peer-reviewed paper) [Conference abstract] 10.1182/blood-2024-198541 Load-bearing source DOI 10.1182/blood-2024-198541
Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy (Blood, ASH Annual Meeting). DOI 10.1182/blood-2024-198541.

Additional context

Study ASTX727-07 trial registry (opens in a new tab) (Clinical-trial registry) NCT04657081 NCT04657081
Study ASTX727-07 trial registry. NCT04657081.

Why Should I Trust This?

1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13